Question · asked by 1 review
Etanercept vs Placebo (subcutaneous): Mean number of oral ulcers
- Population
- People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
- Intervention
- Etanercept
- Comparison
- Placebo (subcutaneous)
- Outcome
- Mean number of oral ulcers
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Etanercept (systemic; 25 mg subcutaneously twice weekly for 4 weeks) vs Placebo (subcutaneous) Mean number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… · Males only Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane All outcomes | Melikoglu 2005 (etanercept 25 mg s.c. twice weekly for 4 weeks vs placebo, 40 male patients; high risk of reporting bias): authors reported a statistically significant difference in mean number of oral ulcers with… | 1 study · 40 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes | 2013-10 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.